Allison, D., Mentore, J., Moonseong, H., et al (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686–1696.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al
(2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.
British Medical Association & Royal Pharmaceutical Society of Great Britain (2006) British National Formulary
. BMJ Books & Pharmaceutical Press.
Brown, S. (1997) Excess mortality of schizophrenia: a meta-analysis. British Journal of Psychiatry, 171, 502–508.
Disability Rights Commission (2006) Equal Treatments: Closing the Gap. Disability Rights Commission.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486–2497.
Fenton, W. & Chavez, M. (2006) Medication induced weight gain and dyslipidaemia in patients with schizophrenia. American Journal of Psychiatry, 163, 1697–1704.
Kane, J., Honifeld, G., Singer, J., et al (1988) Clozapine for the treatment resistant schizophrenic. Archives of General Psychiatry, 45, 789–796.
Lakka, H., Laaksonen, D., Lakka, T., et al (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle aged men. JAMA, 288, 2709–2716.
Lamberti, S., Olson, D., Crilly, J., et al (2006) Prevalence of the metabolic syndrome among patients receiving clozapine therapy. American Journal of Psychiatry, 163, 1273–1276.
Newcomer, J. (2005) Second-generation (atypical) antipsychotics and metabolic effects. A comprehensive literature review. CNS Drugs, 19 (suppl 1) 1–93.
Smith, H. & White, T. (2004) Low glycaemic index diet in patients prescribed clozapine: pilot study. Psychiatric Bulletin, 28, 292–294.